Nitric Oxide Donor Doxorubicins Accumulate into Doxorubicin-Resistant Human Colon Cancer Cells Inducing Cytotoxicity

ACS Medicinal Chemistry Letters
2011.0

Abstract

Products 4 and 5, obtained by conjugation of doxorubicin with nitric oxide (NO) donor nitrooxy and phenylsulfonyl furoxan moieties, respectively, accumulate in doxorubicin-resistant human colon cancer cells (HT29-dx), inducing high cytotoxicity. This behavior parallels the ability of the compounds to generate NO, detected as nitrite, in these cells. Preliminary immunoblotting studies suggest that the mechanism that underlies the cytotoxic effect could involve inhibition of cellular drug efflux due to nitration of tyrosine residues of the MRP3 protein pump.

Knowledge Graph

Similar Paper

Nitric Oxide Donor Doxorubicins Accumulate into Doxorubicin-Resistant Human Colon Cancer Cells Inducing Cytotoxicity
ACS Medicinal Chemistry Letters 2011.0
Overcoming multidrug resistance by targeting mitochondria with NO-donating doxorubicins
Bioorganic & Medicinal Chemistry 2016.0
Synthesis and evaluation of nitric oxide-releasing DDB derivatives as potential Pgp-mediated MDR reversal agents in MCF-7/Adr cells
Bioorganic & Medicinal Chemistry Letters 2012.0
Synthesis and evaluation of furoxan-based nitric oxide-releasing derivatives of tetrahydroisoquinoline as anticancer and multidrug resistance reversal agents
Bioorganic & Medicinal Chemistry Letters 2011.0
Porphyrins containing nitric oxide donors: Synthesis and cancer cell-oriented NO release
Bioorganic & Medicinal Chemistry Letters 2009.0
Design and Synthesis of 3‘- and 5‘-O-(3-Benzenesulfonylfuroxan-4-yl)-2‘-deoxyuridines:  Biological Evaluation as Hybrid Nitric Oxide Donor−Nucleoside Anticancer Agents
Journal of Medicinal Chemistry 2004.0
Novel Nitric Oxide Donors of Phenylsulfonylfuroxan and 3-Benzyl Coumarin Derivatives as Potent Antitumor Agents
ACS Medicinal Chemistry Letters 2018.0
Doxorubicin-antioxidant co-drugs
Bioorganic & Medicinal Chemistry Letters 2013.0
Hydroxylation at C-3′ of doxorubicin alters the selected phenotype of cellular drug resistance
Bioorganic & Medicinal Chemistry Letters 1995.0
Overcoming doxorubicin-resistance in the NCI/ADR-RES model cancer cell line by novel anthracene-9,10-dione derivatives
Bioorganic & Medicinal Chemistry Letters 2013.0